This is Why 2021 Could be Another Big Year for Psychedelics

Psychedelics such as psilocybin could soon revolutionize the $2.5 trillion mental health market. All thanks to some big catalysts. For one, “Traditional medicines that are treating things like depression, addiction and anxiety really are seeking to numb and mask the issues that surround these illnesses. So, things like Xanax, while they might make you feel better, they can also be highly addictive and are not dealing with the underlying problem,” MindMed’s co-founder and co-CEO JR Rahn told Yahoo.

Two, there’s hope the U.S. could even see even more legalization after Oregon, Oakland and Santa Cruz legalized the use of psilocybin. Three, Canada, which allowed palliative health patients to use psilocybin to relieve end of life suffering will now allow some professionals to use the drug to help develop therapies for future use. In fact, “Health Canada says it granted 16 exemptions to a selection of nurses, doctors, therapists and social workers, allowing them to possess and use psilocybin for personal training without fear of prosecution under the country’s drug laws,” as reported by CBC. These are just some of the major catalysts that could drive even more interest in psychedelics in New Year 2021. As the story gains momentum, some of the top companies to watch include Nova Mentis Life Science Corp. (CSE:NOVA)(OTCPK:LIBFF), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), COMPASS Pathways (NASDAQ:CMPS), Cybin Inc. (NEO:CYBN)(OTC:CLXPF) and Tryp Therapeutics Inc. (CSE:TRYP).

Nova Mentis Life Science Corp. (CSE:NOVA)(OTCPK:LIBFF) BREAKING NEWS : Nova Mentis Life Science Corp. is pleased to announce that it has appointed Dr. Kyle H. Ambert, PhD to its Scientific Advisory Board, effective immediately. Dr. Ambert has also agreed to become a consultant to NOVA and will assist the Company in designing preclinical and clinical autism spectrum disorder (ASD) studies and analyzing their results.

Dr. Ambert is currently Director of Data Science at Nike, Inc. and has extensive experience in data analytics, machine learning, artificial intelligence and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.

Dr. Marvin S. Hausman MD, Chairman of the NOVA Scientific Advisory Board commented, “I am extremely pleased to welcome Dr. Ambert to our team. His enviable expertise in artificial intelligence and data science will be invaluable as we continue our research into autism spectrum disorder (ASD). Dr. Ambert’s knowledge of applied machine learning and deep learning represents a major addition to the Company as we develop the novel, proprietary ‘Pilz ASD Correlate’, a statistically objective biomarker program to measure psychedelic treatment response.”

…